<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77066">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670045</url>
  </required_header>
  <id_info>
    <org_study_id>ML28216</org_study_id>
    <nct_id>NCT01670045</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Indonesia: National Agency for Drug and Food Control (NA-DFC)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center observational study will evaluate the use and efficacy of
      RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis.
      Eligible patients initiated on RoActemra/Actemra treatment according to the licensed label
      will be followed for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Proportion of patients on RoActemra/Actemra at 6 months</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Response according to total joint count evaluation by DAS28/EULAR/SDAI/CDAI/ACR</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reduction/withdrawal of DMARDs and/or corticosteroids</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of disease activity</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of dose modifications/interruptions</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">44</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis initiating treatment with RoActemra/Actemra
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria

          -  Patient in whom the treating physician has made the decision to commence
             RoActemra/Actemra treatment in accordance with the local label (DMARD-IR, TNF-IR or
             need of RoActemra/Actemra monotherapy); this can include patients who have received
             RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit

        Exclusion Criteria:

          -  Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment
             visit

          -  Patients who have previously received RoActemra/Actemra in a clinical trial or for
             compassionate use

          -  Patients who have received treatment with an investigational agent within 4 weeks (or
             5 half-lives of the investigational agent, whichever is longer) before starting
             treatment with RoActemra/Actemra

          -  Patients with a history of autoimmune disease or any joint inflammatory disease other
             than rheumatoid arthritis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Balikpapan</city>
        <zip>76121</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Central Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Central Java</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denpasar</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malang</city>
        <zip>65111</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manado</city>
        <zip>95115</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medan</city>
        <zip>20157</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
